secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexaria Bioscience Corp. (LEXX)
CIK:        0001348362
Form:       8-K
Filed at:   2023-08-28T23:59:59+00:00
Accession:  0001640334-23-001644
Event type: regulatory
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexaria regains Nasdaq minimum bid price compliance; plans reverse split meeting
--------------------------------------------------------------------------------

- Received Nasdaq letter confirming bid price >=$1.00 for 10 consecutive days through Aug 23, 2023.
- Regained compliance with Nasdaq Listing Rule 5550(a)(2) for continued listing.
- Company called special meeting to approve possible reverse stock split by May 31, 2024.
- Intends to proceed with reverse split proposal to enable quick future compliance and attract investment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348362/000164033423001644/0001640334-23-001644-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348362/000164033423001644/lxrp_8k.htm
  HTML page:      https://secwatch.observer/filing/0001640334-23-001644

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer